In a long-awaited milestone in the gene therapy space, the Food and Drug Administration (FDA) approved two gene therapies to
Continue Reading Gene Therapy Approvals Gain Steam in 2023: FDA Approves First Gene Therapies for Sickle Cell Disease
Gene Therapy Approvals Gain Steam in 2023: Milestones in Second Half Pave Way for Transformative 2024
Gene therapy is part of a new wave of medicine that approaches disease treatment by addressing the root causes rather
Continue Reading Gene Therapy Approvals Gain Steam in 2023: Milestones in Second Half Pave Way for Transformative 2024
The Evolving Gene Editing Landscape: From Research Tool to Market
Gene therapies have been the subject of tremendous scientific research and investment. With hundreds of clinical trials in progress and
Continue Reading The Evolving Gene Editing Landscape: From Research Tool to Market
PTAB Sides with Broad in Patent Dispute over CRISPR Gene Editing of Eukaryotic Cells
On February 28, 2022, the Patent Trial and Appeal Board (PTAB) issued a decision in Interference No. 106,115, which granted
Continue Reading PTAB Sides with Broad in Patent Dispute over CRISPR Gene Editing of Eukaryotic Cells
Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
Vertex Pharmaceuticals and Mammoth Biosciences, a Brisbane, California-based genetic research company, announced a new collaboration for the development of in
Continue Reading Vertex and Mammoth Biosciences Ink $700M Deal for Ultra-Small CRISPR Systems
Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform